By Josh BeckermanNRx Pharmaceuticals Inc. shares were down 8%, to 53 cents, after the company said the U.S. Food and Drug Administration denied the Breakthrough Therapy designation request for Zyesami (aviptadil) for patients with Covid-19. The stock declined 58% on May 26 after unfavorable results from a Zyesami study. NRx has said it would evaluate options for Zyesami in protecting the lung in other respiratory disorders and in other therapeutic areas. NRx has focused on NRX-101 for treatment of severe bipolar depression in patients with acute suicidal ideation and behavior. Write to Josh Beckerman at josh.beckerman@wsj.com(END) Dow Jones NewswiresJune 13, 2022 15:09 ET (19:09 GMT)Copyright (c) 2022 Dow Jones & Company, Inc.

Source: Wall Street Journal June 14, 2022 01:15 UTC